Follow
Adam JN Raymakers
Adam JN Raymakers
Brigham and Women's Hospital and Harvard Medical School
Verified email at bwh.harvard.edu
Title
Cited by
Cited by
Year
The cost effectiveness of human papillomavirus vaccines: a systematic review
K Seto, F Marra, A Raymakers, CA Marra
Drugs 72, 715-743, 2012
1192012
Comparison of outpatient and home‐based exercise training programmes for COPD: a systematic review and meta‐analysis
F Wuytack, D Devane, E Stovold, M McDonnell, M Casey, TJ McDonnell, ...
Respirology 23 (3), 272-283, 2018
852018
Cost utility of early versus delayed laparoscopic cholecystectomy for acute cholecystitis
A Johner, A Raymakers, SM Wiseman
Surgical Endoscopy, 1-7, 2012
822012
Cost-effectiveness analyses of lung cancer screening strategies using low-dose computed tomography: a systematic review
AJN Raymakers, J Mayo, S Lam, JM FitzGerald, DGT Whitehurst, LD Lynd
Applied health economics and health policy 14, 409-418, 2016
772016
The impact of statin drug use on all-cause mortality in patients with COPD: a population-based cohort study
AJN Raymakers, M Sadatsafavi, DD Sin, MA De Vera, LD Lynd
Chest 152 (3), 486-493, 2017
522017
Inhaled corticosteroids and the risk of lung cancer in COPD: a population-based cohort study
AJN Raymakers, M Sadatsafavi, DD Sin, JM FitzGerald, CA Marra, ...
European Respiratory Journal 53 (6), 2019
482019
Economic and humanistic burden of external genital warts
AJN Raymakers, M Sadatsafavi, F Marra, CA Marra
Pharmacoeconomics 30, 1-16, 2012
462012
The effectiveness of physiologically based early warning or track and trigger systems after triage in adult patients presenting to emergency departments: a systematic review
F Wuytack, P Meskell, A Conway, F McDaid, N Santesso, FG Hickey, ...
BMC emergency medicine 17, 1-14, 2017
432017
Do inhaled corticosteroids protect against lung cancer in patients with COPD? A systematic review
AJN Raymakers, N McCormick, CA Marra, JM Fitzgerald, D Sin, LD Lynd
Respirology 22 (1), 61-70, 2017
362017
Reducing potentially inappropriate prescribing for older people in primary care: cost-effectiveness of the OPTI-SCRIPT intervention
P Gillespie, B Clyne, A Raymakers, T Fahey, CM Hughes, SM Smith
International Journal of Technology Assessment in Health Care, 1-10, 2017
292017
Understanding cancer survivors’ reasons to medicate with cannabis: A qualitative study based on the theory of planned behavior
H McTaggart‐Cowan, C Bentley, A Raymakers, R Metcalfe, P Hawley, ...
Cancer Medicine 10 (1), 396-404, 2021
282021
Factors influencing health-related quality of life in patients with Type 1 diabetes
AJN Raymakers, P Gillespie, MC O’Hara, MD Griffin, SF Dinneen
Health and quality of life outcomes 16, 1-5, 2018
242018
Diagnostic strategies incorporating computed tomography angiography for pulmonary embolism: a systematic review of cost-effectiveness analyses
AJN Raymakers, J Mayo, CA Marra, M FitzGerald
Journal of thoracic imaging 29 (4), 209-216, 2014
232014
Health‐related quality of life in oncology drug reimbursement submissions in Canada: A review of submissions to the pan‐Canadian Oncology Drug Review
AJN Raymakers, DA Regier, SJ Peacock
Cancer 126 (1), 148-155, 2020
202020
Statin use and lung cancer risk in chronic obstructive pulmonary disease patients: a population-based cohort study
AJN Raymakers, DD Sin, M Sadatsafavi, JM FitzGerald, CA Marra, ...
Respiratory Research 21 (1), 1-11, 2020
152020
Modelling uncertainty in survival and cost-effectiveness is vital in the era of gene therapies: the case of axicabtagene ciloleucel
AJN Raymakers, DA Regier, SJ Peacock
Health Policy and Technology 8 (2), 103-104, 2019
132019
A cost-effectiveness analysis of a proactive management strategy for the Sprint Fidelis recall: a probabilistic decision analysis model
J Bashir, S Cowan, A Raymakers, M Yamashita, M Danter, A Krahn, ...
Heart Rhythm 10 (12), 1761-1767, 2013
122013
Evidence, values, and funding decisions in Canadian cancer systems
SJ Peacock, DA Regier, AJN Raymakers, KKW Chan
Healthcare Management Forum 32 (6), 293-298, 2019
102019
Defining a core data set for the economic evaluation of precision oncology
S Pollard, D Weymann, B Chan, M Ehman, S Wordsworth, J Buchanan, ...
Value in Health 25 (8), 1371-1380, 2022
92022
High cost of chimeric antigen receptor T-cells: challenges and solutions
ERS Cliff, AH Kelkar, DA Russler-Germain, FA Tessema, AJN Raymakers, ...
American Society of Clinical Oncology Educational Book 43, e397912, 2023
82023
The system can't perform the operation now. Try again later.
Articles 1–20